Why Were Not Close to AI Drugs Yet | Isomorphic Labs @WeightsBiases
Why Were Not Close to AI Drugs Yet | Isomorphic Labs  @WeightsBiases
Uploaded February 2026 | Updated September 2026, 2 weeks ago
Drug design isn't one ML problem; it's a wide variety of challenges requiring specific system representations.

Isomorphic Labs' Sergei Yakneen and Max Jaderberg explain why AlphaFold 2 was just the beginning. There are 10+ more breakthroughs needed to design drugs.
Why Were Not Close to AI Drugs Yet | Isomorphic LabsW&B Models: Track all ML experimentsThe CEO Behind the Fastest-Growing AI Inference CompanyW&B Inference: test open-source LLMs in SECONDSW&B Models: AlertsHe Built A $15B Company Without A Sales TeamWhy I would never touch a peptideLarge-scale agentic quant research with Weights & BiasesWhy Big Tech Buys GPUs From CoreWeave | Corey SandersRun the model, not the risk: Powering private inference for enterprise AI anywhereW&B Inference: Access CoreWeave-hosted open-source models in W&B WeaveOne size doesn’t fit all: Building AI agents specialized for your enterprise
Weights & Biases |

Why We're Not Close to AI Drugs Yet | Isomorphic Labs

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER